CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 82.12% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money

Trade AstraZeneca PLC - USD - AZN CFD

69.69
1.04%
Market Trading Hours* (UTC) Open now
Closes on Monday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
Trading сonditions
Spread 0.13
Long position overnight fee

Long position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment -0.023512 %
Charges from full value of position ($-4.47)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.023512%
Short position overnight fee

Short position overnight funding adjustment


Margin. Your investment $1,000.00
Overnight funding adjustment 0.00129 %
Charges from full value of position ($0.25)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.00129%
Overnight fee time 22:00 (UTC)
Min traded quantity 0.1
Currency USD
Margin 5.00%
Stock exchange United States of America
Commission on trade 0%

Key Stats
Prev. Close 69
Open 69.67
1-Year Change 3.94%
Day's Range 69.67 - 70.14
  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 24, 2025 69.00 0.03 0.04% 68.97 69.42 68.78
Jan 23, 2025 68.52 -0.04 -0.06% 68.56 68.74 68.09
Jan 22, 2025 68.12 0.27 0.40% 67.85 68.28 67.62
Jan 21, 2025 67.88 0.22 0.33% 67.66 68.32 67.51
Jan 17, 2025 66.55 -1.13 -1.67% 67.68 67.68 66.45
Jan 16, 2025 66.84 1.01 1.53% 65.83 66.93 65.69
Jan 15, 2025 65.61 0.17 0.26% 65.44 65.82 64.98
Jan 14, 2025 65.33 0.32 0.49% 65.01 65.60 64.15
Jan 13, 2025 65.66 -0.24 -0.36% 65.90 66.15 65.58
Jan 10, 2025 66.94 -0.03 -0.04% 66.97 67.51 66.79
Jan 8, 2025 66.51 0.43 0.65% 66.08 66.68 65.60
Jan 7, 2025 66.48 -0.36 -0.54% 66.84 67.26 66.48
Jan 6, 2025 66.69 0.09 0.14% 66.60 67.51 66.30
Jan 3, 2025 66.19 -0.14 -0.21% 66.33 66.41 66.06
Jan 2, 2025 65.80 -0.08 -0.12% 65.88 66.33 65.76
Dec 31, 2024 65.46 0.67 1.03% 64.79 65.96 64.79
Dec 30, 2024 65.51 -0.48 -0.73% 65.99 65.99 65.27
Dec 27, 2024 66.21 0.40 0.61% 65.81 66.35 65.71
Dec 26, 2024 66.47 0.96 1.47% 65.51 66.60 65.51
Dec 24, 2024 66.20 0.22 0.33% 65.98 66.44 65.84

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 3:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

AstraZeneca - USD Company profile

About AstraZeneca plc (ADR)

AstraZeneca PLC (AstraZeneca) is a patient-focused biopharmaceutical company. The Company focuses on discovery and development, manufacturing and commercialization of prescription medicines, primarily for the treatment of diseases. The Company is focused on three main therapy areas: Oncology; Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Its pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development. The Company has access to technologies, both internally and through its various collaborations. Its technologies include acoustic tube technology, advanced molecular imaging, cryo-electron microscopy (cryo-EM), functional genomics, multi-omics and AstraZeneca iLab. The Company’s acoustic tube technology helps it to handle and process millions of compounds for biological screening. Its AstraZeneca iLab is its prototype of an automated medicinal chemistry laboratory.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, AstraZeneca plc (ADR) revenues increased 41% to $37.42B. Net income decreased 96% to $112M. Revenues reflect Farxiga segment increase of 53% to $3B, Calquenc segment increase from $522M to $1.24B, Tagrisso segment increase of 16% to $5.02B, United States segment increase of 35% to $12.05B, United Kingdom segment increase of 86% to $3.25B, Sweden segment increase from $1.03B to $2.32B.

Equity composition

Ordinary Shares $.25, 12/10, 2.4B auth. 1,409,023,452 issd.Insiders own 0.37%. 5/93, Company formed through spin-off of a wholly-owned subsidiary ICI Zeneca Limited. Basis: 1-for-1. *FY'01 Q's are restated for deferred tax. 07/15, 2-for-1, Stock Split.

Industry: Pharmaceuticals (NEC)

1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB

People also watch

Gold

2,743.73 Price
-1.040% 1D Chg, %
Long position overnight fee 0.0056%
Short position overnight fee -0.0139%
Overnight fee time 22:00 (UTC)
Spread 0.30

ETH/USD

3,142.63 Price
-4.990% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 1.75

XRP/USD

2.97 Price
-4.590% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 0.01480

US100

21,231.00 Price
-2.720% 1D Chg, %
Long position overnight fee -0.0235%
Short position overnight fee 0.0013%
Overnight fee time 22:00 (UTC)
Spread 1.8

Still looking for a broker you can trust?

Join the 690,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading